Anagrelide is a selective thrombopoietin inhibitor primarily used to treat thrombocytosis caused by primary thrombocytosis (ET) and other myeloproliferative neoplasms (MPN).

Ⅰ. Drug name

1. Product Name: AGRYLIN

2. Common name: Anagrelide

Ⅱ. indication

Used to treat thrombocytosis secondary to myeloproliferative tumors, to reduce elevated platelet counts, decrease the risk of thrombosis, and improve related symptoms, including thrombotic bleeding events.

Ⅲ. Specifications and characteristics

Specification: 0.5mg capsules.

Ⅳ. main ingredients

Active ingredient: Anagrelide.

Ⅴ. Usage and Dosage

1. Adult starting dose: 0.5mg four times daily or 1mg twice daily.

2. Initial dose for pediatric patients: 0.5mg per day.

3. Maintenance dose: Adjust the dose according to platelet response to maintain platelet count below 600000/uL, with an ideal range of 150000/uL to 400000/uL.

Ⅵ. Dose adjustment

1. Dose escalation: not exceeding 0.5mg/day per week, maximum dose not exceeding 10mg/day or 2.5mg per dose.

2. Liver function impairment: The initial dose for patients with moderate liver function impairment is 0.5mg/day, and the dose can be gradually increased according to tolerance, but the weekly increase should not exceed 0.5mg/day; Avoid using for patients with severe liver function impairment.

Ⅶ. Medication precautions

1. Before and after meals: It is not explicitly stated whether medication should be taken before or after meals, but food can affect drug absorption (Cmax decreased by 14%, AUC increased by 20%).

2. Missed medication: The handling of missed medication has not been clearly stated. It is recommended to follow the conventional principle of handling missed medication, which is to skip the missed dose near the next medication time.

3. Vomiting: If vomiting occurs after taking medication and it is not clearly stated whether additional medication is needed, it is recommended to decide based on the interval between the time of vomiting and the next medication.

Ⅷ. Medication for special populations

1. Pregnancy period: According to animal experimental data, it may have an impact on the fetus, and the use during pregnancy should be weighed against the pros and cons.

2. Breastfeeding period: It is recommended that lactating women avoid breastfeeding during treatment and for one week after discontinuing medication.

3. Reproductive potential of females and males: may affect female fertility.

4. Pediatric use: Safety and efficacy have been established for children aged 7 and above, but data for children under 7 years old is insufficient.

5. Elderly patients: Patients aged 65 and above do not need to adjust the starting dose, but close monitoring is required.

Ⅸ. adverse reaction

Common adverse reactions (incidence ≥ 25%): headache, palpitations, diarrhea, fatigue, edema, nausea, abdominal pain, dizziness, pain, difficulty breathing, cough, bloating, vomiting, fever, peripheral edema, rash, chest pain, decreased appetite, tachycardia, discomfort, abnormal sensation, back pain, itching, indigestion.

Ⅹ. contraindication

There are no clear contraindications.

Ⅺ. Drug interactions

1. Medications that prolong QT: Avoid co administration with drugs that may prolong the QT interval.

2. PDE3 inhibitors: Avoid co administration with other PDE3 inhibitors.

3. Aspirin and drugs that increase the risk of bleeding: When used in combination with aspirin or other drugs that increase the risk of bleeding, the risk of bleeding increases.

4. CYP1A2 inhibitors and inducers: CYP1A2 inhibitors may increase the amount of Anagar thunderstorm exposure, while CYP1A2 inducers may decrease the amount of Anagar thunderstorm exposure.

Ⅻ. storage method

1. Stored at 25 ° C (77 ° F), with a permissible range of 15 ° C to 30 ° C (59 ° F to 86 ° F).

2. Store in a dark container.

Anagrelideinformation